| Drug General Information |
| Drug ID |
D0X0CS
|
| Former ID |
DNC006897
|
| Drug Name |
2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H17NO4
|
| Canonical SMILES |
CC(C)C1=C(C(=C(C(=C1)C(=O)NC2=CC=CC=C2)O)O)O
|
| InChI |
1S/C16H17NO4/c1-9(2)11-8-12(14(19)15(20)13(11)18)16(21)17-10-6-4-3-5-7-10/h3-9,18-20H,1-2H3,(H,17,21)
|
| InChIKey |
HMVKMSUSFWLQLX-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Apoptosis regulator Bcl-2 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
HIF-1 signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Protein processing in endoplasmic reticulum
|
|
PI3K-Akt signaling pathway
|
|
Apoptosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
Focal adhesion
|
|
Neurotrophin signaling pathway
|
|
Cholinergic synapse
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Colorectal cancer
|
|
Prostate cancer
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
TCR Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
PANTHER Pathway
|
Apoptosis signaling pathway
|
|
Oxidative stress response
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
Ceramide signaling pathway
|
|
Direct p53 effectors
|
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
ATF-2 transcription factor network
|
|
C-MYB transcription factor network
|
|
HIV-1 Nef: Negative effector of Fas and TNF-alpha
|
|
Caspase Cascade in Apoptosis
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
EPO signaling pathway
|
|
IL2 signaling events mediated by STAT5
|
|
Validated targets of C-MYC transcriptional repression
|
|
Reactome
|
Activation of BAD and translocation to mitochondria
|
|
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
|
|
The NLRP1 inflammasome
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Senescence and Autophagy in Cancer
|
|
IL-2 Signaling Pathway
|
|
FAS pathway and Stress induction of HSP regulation
|
|
Focal Adhesion
|
|
Kit receptor signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
|
|
Apoptosis
|
|
Nanoparticle triggered autophagic cell death
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Integrated Pancreatic Cancer Pathway
|
|
Corticotropin-releasing hormone
|
|
Interleukin-11 Signaling Pathway
|
|
Prostate Cancer
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Intrinsic Pathway for Apoptosis
|
|
Apoptosis Modulation and Signaling
|
|
TP53 Network
|
|
Influenza A virus infection
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | J Med Chem. 2006 Oct 19;49(21):6139-42.Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. |
|---|
